Mr. Termeer was a leader of the biotechnology industry and a mentor to many entrepreneurs, executives and researchers, including the X4 team. He had a long and illustrious career with numerous contributions to the biotech community until his death in May 2017. He was the Chairman, President and Chief Executive Officer of Genzyme Corporation, a Fortune 500 company, a position he held for over 25 years before he retired in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer served as a board member of Massachusetts Institute of Technology Corporation and on its executive committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, a member of the Board of Fellows of Harvard Medical School, and on the board of the Biotechnology Industry Organization (BIO). He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Medical Simulation Corporation. He was a Founder of X4 Pharmaceuticals and several other Boston-area biotechnology companies. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors and he is a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. He was elected a fellow of the American Academy of Arts and Sciences in 1999. Mr. Termeer studied economics at Erasmus University in the Netherlands and earned an MBA from the Darden School at the University of Virginia.
Keith Flaherty, MD
Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Cancer Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer and to define the mechanisms of action and resistance of novel therapies. Dr. Flaherty received his medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
Renato Skerlj, PhD
Dr. Skerlj has over 20 years of pharmaceutical experience in the discovery and development of novel therapies. Dr. Skerlj is Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics, Inc (LTI). Prior to LTI, he was the Head of Small Molecule Discovery at Genzyme and prior to joining Genzyme, was part of the executive team at AnorMED, a publicly-traded company acquired by Genzyme for $580 million in 2006. Dr. Skerlj is an inventor of both plerixafor, a stem cell mobilizer approved in 2008, and ertapenem, an anti-bacterial approved in 2001. Dr. Skerlj earned his doctorate from the University of British Columbia and completed a fellowship at the University of Oxford in Dr. Stephen Davies’ laboratory.
Richard Peters, MD, PhD
Dr. Peters is currently the President and CEO of Merrimack Pharmaceuticals. Prior to that, he was Senior Vice President and Head of Rare Diseases at Sanofi Genzyme and the Division Medical Officer of Sanofi’s Hematology and Oncology Division. Dr. Peters has over 20 years of biotech experience including roles of increasing responsibility in medical affairs at Amgen, Onyx and Genzyme. Earlier in his career, Dr. Peters was CEO of Mednav. Dr. Peters graduated with his MD and PhD from Medical University of South Carolina.
Paula Ragan, PhD
Dr. Ragan is a founder, as well as the Chief Executive Officer and President of X4. She has more than 18 years of experience building companies in the biotechnology industry. Most recently, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc (LTI), an Atlas Venture portfolio company, where she led the company’s business development activities. Prior to LTI, Dr. Ragan held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her BS in Mechanical Engineering from Tufts University and her PhD from MIT. She completed post-doctoral studies at Harvard Medical School.